09:57 AM EST - Cipher Pharmaceuticals Inc. : Today announced that its New Drug Submission for A-101 40% topical solution for the treatment of raised seborrheic keratoses has been accepted for review by Health Canada. Cipher acquired the exclusive Canadian rights to distribute and commercialize A-101 40% from Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in April 2018. Cipher Pharmaceuticals Inc.
shares T.CPH are trading up $0.02 at $1.73.
